21 results
6-K
EX-99.1
OBSVF
ObsEva SA
11 Jan 21
ObsEva Provides Update on Yselty® (Linzagolix) Clinical Development Program
7:05am
and enrollment for EDELWEISS 2 in the US has been increasingly challenging, particularly in the context of the persisting difficult environment
6-K
EX-99.2
OBSVF
ObsEva SA
6 May 21
Index to Unaudited Condensed Consolidated Financial Statements
6:03am
the related EDELWEISS 2 clinical trial, due to challenging patient screening and enrollment, as well as persisting difficult environment of the ongoing … clinical trial, due to challenging patient screening and enrollment, as well as persisting difficult environment of the ongoing pandemic. Enrollment
6-K
EX-99.2
OBSVF
ObsEva SA
5 Aug 21
Index to Unaudited Condensed Consolidated Financial Statements
6:04am
patient screening and enrollment, as well as persisting difficult environment of the ongoing COVID-19 pandemic. We are planning to conduct, as soon … screening and enrollment, as well as persisting difficult environment of the ongoing pandemic. Enrollment delays may further occur for ongoing trials
6-K
EX-99.2
OBSVF
ObsEva SA
4 Nov 21
Index to Unaudited Condensed Consolidated Financial Statements
7:21am
as the persisting difficult environment of the ongoing COVID-19 pandemic.
In June 2021, we presented 52-week data from the two pivotal Phase 3 trials … with patient enrollment, as well as the persisting difficult environment of the ongoing pandemic. Enrollment delays may further occur for ongoing trials, and we
6-K
OBSVF
ObsEva SA
17 May 22
Index to Unaudited Condensed Consolidated Financial Statements
7:00am
;
changes in a specific country's or region's political or economic environment;
trade protection measures, import or export licensing requirements or other
6-K
EX-99.2
kyjbx
17 May 22
Index to Unaudited Condensed Consolidated Financial Statements
7:00am
6-K
EX-1.1
6ulxqahr lru4dq11cl4
22 Jun 18
ObsEva Announces Launch of ProposedFollow-on Public Offering
4:06pm
10-K
ha2wj3
31 Mar 23
Annual report
4:01pm
6-K
EX-1.1
nq8ihdy
5 Mar 21
Current report (foreign)
8:15am
6-K
EX-1.1
s1fex1xisnrfb
8 Sep 20
ObsEva Announces $20.0 Million Underwritten Offering and Concurrent Private Placement
7:40am
20-F
6qtol2b0s kht
21 Apr 17
Annual report (foreign)
12:00am
6-K
EX-99.2
w1czgawkv6
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
9:27am
6-K/A
EX-99.2
rwe1f1f
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
5:24pm
6-K
EX-99.3
z1eebwt2kb7o5h0u33d5
28 Jan 22
ObsEva Announces Corporate Updates
5:16pm
F-1
mhq16zfvhaacs irdtm
30 Dec 16
Registration statement (foreign)
12:00am